Development of Renal Cell Carcinoma in Living Donor Kidney Grafts

Tydén, G; Wernersson, Annika; Sandberg, J; Berg, Ulla

doi:10.1097/00007890-200012150-00018

Cited by 61 publications

(41 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, there was no increase in the incidence of targeted AE. Despite isolated reports of AE in recipients receiving rhGH, the lack of significant evidence of AE in the controlled studies [27,28,29,30], in addition to the current report, should be reassuring despite the recent report of a renal malignancy in two recipients receiving long-term rhGH [32]. A recent analysis of all available data regarding any relationship between rhGH treatment and renal malignancy by Mehls et al [33] was unable to substantiate any relationship.…”

Section: Discussioncontrasting

confidence: 55%

Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry

Fine

Stablein

2005

Pediatr Nephrol

View full text Add to dashboard Cite

Data from the NAPRTCS database were analyzed for growth, allograft function, and targeted adverse events (AE) over a 5-year period in 513 recipients who received recombinant human growth hormone (rhGH) treatment and compared with the outcome of 2,263 concurrent controls who did not receive rhGH. Recipients less than 10 years of age grew better than older recipients. Final adult height was superior in the rhGH-treated group compared with the control group. Allograft function and graft failure rate was similar in the rhGH-treated and control groups. No increased incidence of AE was noted in the rhGH-treated group. rhGH is effective and safe for use in growth-retarded pediatric renal allograft recipients.

show abstract

Section: Discussioncontrasting

confidence: 55%

Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry

Fine

Stablein

2005

Pediatr Nephrol

View full text Add to dashboard Cite

show abstract

“…The development of RCC in renal grafts is uncommon in transplantation patients and is more often described in their native kidneys ( 19,20 ). Researchers in the two largest kidney transplant series previously published to date ( 9,21 ), including 1250 and 1073 patients, reported only three and fi ve cases of RCC clear cell carcinoma at biopsy 2 years after successful RF ablation.…”

Section: Discussionmentioning

confidence: 99%

De Novo Renal Tumors Arising in Kidney Transplants: Midterm Outcome after Percutaneous Thermal Ablation

Cornelis

Buy²,

André³

et al. 2011

Radiology

View full text Add to dashboard Cite

Purpose:To retrospectively evaluate the midterm outcome of patients treated for primary renal cell carcinomas arising in kidney transplants with minimally invasive techniques. Materials and Methods:The institutional review board of each participating institution approved this retrospective study and waived informed consent . This study was HIPAA compliant. A request for cases through the European Society of Urogenital Radiology network was made to institutions for patients who fi t the requirements outlined by the authors, and a prospective follow-up of recipients was performed. Twenty-four tumors were identifi ed that developed in the renal allograft of 20 patients from 11 institutions who were treated with radiofrequency ablation ( n = 19) or cryoablation ( n = 5) between 2003 and 2010. Maximal diameter of masses was 6-40 mm (median, 19.5 mm). Twenty masses were solid, and four were type 4 cystic masses. Preablation biopsy was performed for solid tumors only. All images and biologic and biopsy reports were retrospectively reviewed. Significant differences were determined by using a paired t test before and after ablation. Results:Mean follow-up was 27.9 months (range, 7-71 months). Histopathologic examination revealed papillary carcinoma in 17 patients and clear cell carcinoma in three. Tumors were successfully treated with ultrasonographic guidance in six patients, with computed tomographic guidance in 10 patients, and with both in four patients. One case of infection of the tumor site and one case of transitory genitofemoral nerve injury were the only reported complications.No signifi cant change of renal function was noted. Subsequent imaging follow-up did not reveal any case of recurrence in the ablative site. Conclusion:Percutaneous thermal ablation of renal tumors occurring in renal grafts is effective, with low morbidity.q RSNA, 2011

show abstract

“…There are three case reports of children with de novo renal cell carcinoma in their transplant kidneys [15,16]. Two of these were included in the above review.…”

Section: Discussionmentioning

confidence: 99%

Association of renal adenocarcinoma and BK virus nephropathy post transplantation

Kausman

Somers

Francis

et al. 2004

Pediatric Nephrology

View full text Add to dashboard Cite

While most BK virus infections are asymptomatic, immunosuppression has been associated with BK virus reactivation and impaired graft function or ureteric ulceration in renal transplant patients and hemorrhagic cystitis in bone marrow transplant patients. Oncogenicity is also postulated and this is the first report of a child with a carcinoma of the donor renal pelvis following BK virus allograft nephropathy. Removal of the primary tumor and cessation of immunosuppression led to regression of secondary tumors and a return to health.

show abstract

Development of Renal Cell Carcinoma in Living Donor Kidney Grafts

Cited by 61 publications

References 15 publications

Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry

Long-term use of recombinant human growth hormone in pediatric allograft recipients: a report of the NAPRTCS Transplant Registry

De Novo Renal Tumors Arising in Kidney Transplants: Midterm Outcome after Percutaneous Thermal Ablation

Association of renal adenocarcinoma and BK virus nephropathy post transplantation

Contact Info

Product

Resources

About